Amendments To The Specification

Please replace the clause beginning at page 5, line 3 with the following amended clause:

--(x) cycloalkylalkyl, ~~**cycloalkylalkynyl**~~ **cycloalkylalkenyl** and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino; --

Please replace the clause beginning at page 22, line 24 with the following amended clause:

-- (l) cycloalkylalkyl, ~~**cycloalkylalkynyl**~~ **cycloalkylalkenyl** and cycloalkylalkynyl, all optionally substituted with alkyl, halo, hydroxy or amino; --

Please replace the paragraph beginning at page 27, line 12 with the following amended paragraph:

--Reaction of the 2-keto-3-phenylaminoacrylonitrile of formula 2 with a hydrazine of formula 3 provides a 5-amino-4-ketopyrazole of formula 4. This reaction is generally carried out in a polar solvent such as ethanol, isopropanol, and the like. Aryl/heteroaryl hydrazines of formula [[2]] 3 such as 2- or 3-chlorophenylhydrazine, 2-,3-, or 4-fluorophenylhydrazine, phenylhydrazine, 2-hydrazinopyridine, 2-hydrazinobenzothiazole, 2-hydrazinoquinoline etc., are commercially available. --

Please replace the paragraph beginning at page 30, line 6 with the following amended paragraph:

--A compound of Formula (I) where R^3 is heteroalkenyl, heteroalkynyl, heterocyclylalkenyl or heterocyclylalkynyl can be prepared by reacting a compound of formula 4 where Z is halo with a heteroalkene, heteroalkyne, heterocyclylalkene or heterocyclylalkyne respectively in the presence of

a palladium (II) catalyst such as dichlorobis(triphenylphosphine)-palladium (II) in an organic base such as diisopropylamine, and the like. Heteroalkenes, heteroalkynes such as allyl alcohol, propargyl alcohol, 3-butyn-1-ol, propargylamine are commercially available. Heterocyclylalkyne can be prepared by reacting an alkynyl halide with a heterocycle. For example, ~~2-morpholin-1-ylprop-1-yne~~ 3-morpholin-1-ylprop-1-yne can be prepared by reacting propargyl bromide with morpholine. Reduction of the double or triple bond under catalytic hydrogenation reaction conditions provides the corresponding compound of Formula (I) where R^3 is a heterocyclylalkyl or heteroalkyl group. --

Please replace the paragraph beginning at page 64, line 14 with the following amended paragraph:

--Replacing piperidine in Step[[1]] 2 above with:
morpholine,
N-methylpiperazine,
4-hydroxypiperidine,
2-aminopyridine,
3-aminopyridine,
4-methylimidazole,
3-aminopyrazole, and
2-methylimidazole;
the following compounds were obtained

Structure	CPD #	HRMS MW	MPt
	131	398.411	127.3-128.5
	132	484.376	238.2-238.6
	133	412.438	141.5-145.5
	134	405.406	

Structure	CPD #	HRMS MW
	135	405.406
	136	393.395
	137	508.405
	138	507.417

--

Please replace the paragraph beginning at page 77, line 8 with the following amended paragraph:

--The ability of the compounds of this invention to inhibit the TNF-α release was determined using a minor modification of the methods ~~described in~~ described in Blifeld, C. et al. *Transplantation*, Vol. **51**(2), 498-503, (1991). --